Detection of Driver and Subclonal Mutations in Myelofibrosis: Clinical Impact on Pharmacologic and Transplant-Based Treatment Strategies
The presence of molecular markers might offer the possibility to evaluate the depth of remission and to monitor minimal residual disease after transplantation.
Expert Rev Hematol
In The Literature
European Journal of Haematology American Journal of Hematology